Therapy Areas: AIDS & HIV
Bayer Animal Health signs global license agreement with NeuroCycle Therapeutics
13 September 2018 -

Health care company Bayer Animal Health GmbH said on Wednesday that it plans to advance innovative allergy treatment options for companion animals under a global license agreement with NeuroCycle Therapeutics Inc (NCT), a privately held biopharmaceutical company.

Through the agreement, Bayer plans to strengthen its portfolio of products for companion animals with new allergy treatment options licensed from NeuroCycle Therapeutics

This license agreement allows Bayer to develop and commercialise novel compounds based on knowledge and intellectual property licensed and controlled by NCT.

The further terms of the agreement have not been disclosed by the companies. Pet ownership is growing around the world including customers' requirement for more effective and convenient treatment options.